• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Obalon Announces Fourth Quarter and Full Year 2017 Financial Results

    Gabrielle Lakusta
    Mar. 06, 2018 08:54AM PST
    Medical Device Investing

    Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Q4-17 total revenue of $3.7 …

    Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017.

    As quoted in the press release:

    • Q4-17 total revenue of $3.7 million grew 32% sequentially over Q3-17
    • Q4-17 U.S. revenue of $2.9 million grew 43% sequentially over Q3-17
    • Highest number of new U.S. accounts sold of any quarter since U.S. launch
    • U.S. reorder revenue exceeds revenue from new account additions for first quarter since U.S. launch
    • Gross margin improved to 54%

    Click here to read the full press release.

    obalon therapeuticsfinancial resultsmedical technologymedical device investingmedical technology company
    The Conversation (0)

    Go Deeper

    AI Powered
    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

    Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

    Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU

    Cleo Diagnostics

    COV:AU

    Ocumetics Technology

    OTC:CA

    Premier Health of America

    PHA:CA

    Bloom Health Partners

    BLMH:CNX

    Applied UV

    AUVI:NSD
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES